Journal: Scientific Reports

Article Title: Multiple host colonization and differential expansion of multidrug-resistant ST25- Acinetobacter baumannii clades

doi: 10.1038/s41598-023-49268-x

Figure Lengend Snippet: ( A) Schematic representation of the phylogenetic relatedness (MrBayes) of 148 ST25 Acinetobacter baumannii genomes using iTOLv6. The tree was midpoint rooted and branch support was > 99%. These genomes belong to the 44 strains sequenced for the present study (red labels), and 104 other strains selected from the NCBI repository. Isolates recovered from animals are indicated by yellow shadowed labels, whereas those from humans of this study by light green. Colors of branches highlight four clades (CI: light orange; CII: blue; CIII: light green; CIV: red). ( B) Zoom on the CIV clade.

Article Snippet: The collection was subsequently enriched with 11 ST25 strains of human origin collected by the French National Reference Center for Antibiotic Resistance (NRC-AR, Besançon hospital, France) between 2013 and 2018 (Supplementary Table ).

Techniques:

Journal: Scientific Reports

Article Title: Multiple host colonization and differential expansion of multidrug-resistant ST25- Acinetobacter baumannii clades

doi: 10.1038/s41598-023-49268-x

Figure Lengend Snippet: ( A) Distribution of acquired antibiotic resistance genes among 148 Acinetobacter baumannii strains belonging to ST25 lineage, according to ResFinder 4.1. The modal number of ARGs was seven. ( B) Acquired antibiotic resistance genes content of the four clades of ST25 lineage. Clade CIV harbored more antibiotic resistance genes than the other clades ( p < 0.01, after Wilcoxon-Mann Whitney test; number of genomes per clade: CI: 11; CII: 35; CIII: 22; CIV: 80). ( C) Scatter plot of the average number of acquired antibiotic resistance genes content of ST25 Acinetobacter baumannii genomes relative to time.

Article Snippet: The collection was subsequently enriched with 11 ST25 strains of human origin collected by the French National Reference Center for Antibiotic Resistance (NRC-AR, Besançon hospital, France) between 2013 and 2018 (Supplementary Table ).

Techniques: MANN-WHITNEY

Journal: Scientific Reports

Article Title: Multiple host colonization and differential expansion of multidrug-resistant ST25- Acinetobacter baumannii clades

doi: 10.1038/s41598-023-49268-x

Figure Lengend Snippet: Heatmap representation of the occurrence of acquired antibiotic resistance genes in 148 ST25 Acinetobacter baumannii genomes according to phylogenetic grouping (number of isolates in each clade CI, n = 11; CII, n = 35; CIII, n = 22; CIV, n = 80) and host origin of the isolates.

Article Snippet: The collection was subsequently enriched with 11 ST25 strains of human origin collected by the French National Reference Center for Antibiotic Resistance (NRC-AR, Besançon hospital, France) between 2013 and 2018 (Supplementary Table ).

Techniques:

Journal: Diabetes Therapy

Article Title: Bioequivalence Evaluation in Healthy Volunteers: New Generic Formulations of Sitagliptin and Sitagliptin–Metformin Fixed-Dose Combination Compared with the Originator Products

doi: 10.1007/s13300-022-01349-2

Figure Lengend Snippet: Bioequivalence assessment of a single dose of sitagliptin 100 mg of the generic test and the originator reference product under fasting conditions

Article Snippet: The sitagliptin study evaluated the bioequivalence of the generic test product “Sitagliptin 100 mg film coated tablet” (containing sitagliptin hydrochloride) with the commercially available originator reference product Januvia 100 mg tablet, distributed by Merck Sharp & Dohme Ltd., Spain (containing sitagliptin phosphate monohydrate).

Techniques:

Journal: Diabetes Therapy

Article Title: Bioequivalence Evaluation in Healthy Volunteers: New Generic Formulations of Sitagliptin and Sitagliptin–Metformin Fixed-Dose Combination Compared with the Originator Products

doi: 10.1007/s13300-022-01349-2

Figure Lengend Snippet: Pharmacokinetic parameters of a single dose of sitagliptin 100 mg tablet of the generic test and the originator reference product administered under fasting condition

Article Snippet: The sitagliptin study evaluated the bioequivalence of the generic test product “Sitagliptin 100 mg film coated tablet” (containing sitagliptin hydrochloride) with the commercially available originator reference product Januvia 100 mg tablet, distributed by Merck Sharp & Dohme Ltd., Spain (containing sitagliptin phosphate monohydrate).

Techniques:

Journal: Diabetes Therapy

Article Title: Bioequivalence Evaluation in Healthy Volunteers: New Generic Formulations of Sitagliptin and Sitagliptin–Metformin Fixed-Dose Combination Compared with the Originator Products

doi: 10.1007/s13300-022-01349-2

Figure Lengend Snippet: Sitagliptin mean plasma concentration over 72 h following a single dose of a 100 mg tablet of the generic test product (black triangle) and the originator reference product (blue circle) under fasted conditions ( N = 29). Test product: Sitagliptin 100 mg film-coated tablet; Reference product: Januvia 100 mg

Article Snippet: The sitagliptin study evaluated the bioequivalence of the generic test product “Sitagliptin 100 mg film coated tablet” (containing sitagliptin hydrochloride) with the commercially available originator reference product Januvia 100 mg tablet, distributed by Merck Sharp & Dohme Ltd., Spain (containing sitagliptin phosphate monohydrate).

Techniques: Concentration Assay

Journal: Diabetes Therapy

Article Title: Bioequivalence Evaluation in Healthy Volunteers: New Generic Formulations of Sitagliptin and Sitagliptin–Metformin Fixed-Dose Combination Compared with the Originator Products

doi: 10.1007/s13300-022-01349-2

Figure Lengend Snippet: Bioequivalence assessment of a single dose of FDC sitagliptin/metformin tablets 50/850 mg of the generic test and the originator reference product under fed conditions

Article Snippet: The sitagliptin study evaluated the bioequivalence of the generic test product “Sitagliptin 100 mg film coated tablet” (containing sitagliptin hydrochloride) with the commercially available originator reference product Januvia 100 mg tablet, distributed by Merck Sharp & Dohme Ltd., Spain (containing sitagliptin phosphate monohydrate).

Techniques:

Journal: Diabetes Therapy

Article Title: Bioequivalence Evaluation in Healthy Volunteers: New Generic Formulations of Sitagliptin and Sitagliptin–Metformin Fixed-Dose Combination Compared with the Originator Products

doi: 10.1007/s13300-022-01349-2

Figure Lengend Snippet: Bioequivalence assessment of a single dose of FDC sitagliptin/metformin tablets 50/1000 mg of the generic test and the originator reference product under fed conditions

Article Snippet: The sitagliptin study evaluated the bioequivalence of the generic test product “Sitagliptin 100 mg film coated tablet” (containing sitagliptin hydrochloride) with the commercially available originator reference product Januvia 100 mg tablet, distributed by Merck Sharp & Dohme Ltd., Spain (containing sitagliptin phosphate monohydrate).

Techniques:

Journal: Diabetes Therapy

Article Title: Bioequivalence Evaluation in Healthy Volunteers: New Generic Formulations of Sitagliptin and Sitagliptin–Metformin Fixed-Dose Combination Compared with the Originator Products

doi: 10.1007/s13300-022-01349-2

Figure Lengend Snippet: Mean plasma concentration over 48 h for sitagliptin ( a ) and metformin ( b ) following a single dose of a 50/850 mg tablet of the generic test product (black triangle) and the originator reference product (blue circle) under fed conditions ( n = 25 for each drug). Test product: sitagliptin/metformin 50/850 mg film-coated tablet; reference product: Janumet 50/850 mg

Article Snippet: The sitagliptin study evaluated the bioequivalence of the generic test product “Sitagliptin 100 mg film coated tablet” (containing sitagliptin hydrochloride) with the commercially available originator reference product Januvia 100 mg tablet, distributed by Merck Sharp & Dohme Ltd., Spain (containing sitagliptin phosphate monohydrate).

Techniques: Concentration Assay

Journal: Diabetes Therapy

Article Title: Bioequivalence Evaluation in Healthy Volunteers: New Generic Formulations of Sitagliptin and Sitagliptin–Metformin Fixed-Dose Combination Compared with the Originator Products

doi: 10.1007/s13300-022-01349-2

Figure Lengend Snippet: Mean plasma concentration over 48 h for sitagliptin ( a ) and metformin ( b ) following a single dose of a 50/1000 mg tablet of the generic test product (black triangle) and the originator reference product (blue circle) under fed conditions ( n = 24 for each drug). Test product: sitagliptin/metformin 50/1000 mg film-coated tablet; reference product: Janumet 50/1000 mg

Article Snippet: The sitagliptin study evaluated the bioequivalence of the generic test product “Sitagliptin 100 mg film coated tablet” (containing sitagliptin hydrochloride) with the commercially available originator reference product Januvia 100 mg tablet, distributed by Merck Sharp & Dohme Ltd., Spain (containing sitagliptin phosphate monohydrate).

Techniques: Concentration Assay

Journal: Diabetes Therapy

Article Title: Bioequivalence Evaluation in Healthy Volunteers: New Generic Formulations of Sitagliptin and Sitagliptin–Metformin Fixed-Dose Combination Compared with the Originator Products

doi: 10.1007/s13300-022-01349-2

Figure Lengend Snippet: PK parameters of sitagliptin and metformin administered after fed administration of a single dose of a 50/850 mg FDC tablet of the generic test and the originator reference product

Article Snippet: The sitagliptin study evaluated the bioequivalence of the generic test product “Sitagliptin 100 mg film coated tablet” (containing sitagliptin hydrochloride) with the commercially available originator reference product Januvia 100 mg tablet, distributed by Merck Sharp & Dohme Ltd., Spain (containing sitagliptin phosphate monohydrate).

Techniques:

Journal: Diabetes Therapy

Article Title: Bioequivalence Evaluation in Healthy Volunteers: New Generic Formulations of Sitagliptin and Sitagliptin–Metformin Fixed-Dose Combination Compared with the Originator Products

doi: 10.1007/s13300-022-01349-2

Figure Lengend Snippet: PK parameters of sitagliptin and metformin after fed administration of a single dose of a 50/1000 mg FDC tablet of the generic test and the originator reference product

Article Snippet: The sitagliptin study evaluated the bioequivalence of the generic test product “Sitagliptin 100 mg film coated tablet” (containing sitagliptin hydrochloride) with the commercially available originator reference product Januvia 100 mg tablet, distributed by Merck Sharp & Dohme Ltd., Spain (containing sitagliptin phosphate monohydrate).

Techniques:

Journal: Diabetes Therapy

Article Title: Bioequivalence Evaluation in Healthy Volunteers: New Generic Formulations of Sitagliptin and Sitagliptin–Metformin Fixed-Dose Combination Compared with the Originator Products

doi: 10.1007/s13300-022-01349-2

Figure Lengend Snippet:

Article Snippet: The sitagliptin study evaluated the bioequivalence of the generic test product “Sitagliptin 100 mg film coated tablet” (containing sitagliptin hydrochloride) with the commercially available originator reference product Januvia 100 mg tablet, distributed by Merck Sharp & Dohme Ltd., Spain (containing sitagliptin phosphate monohydrate).

Techniques: